An interventional study of Therapeutic Exercise in Kidney Diseases and Exercise, sponsored by Universidad de León. Withdrawn at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.
Sponsored by Universidad de León · Not applicable, Interventional, and Treatment
Among 52 studies in Kidney Diseases with a site in Spain — 10 open to participants now, 20 under way, 12 of them phase 3. Kidney Diseases · Spain.
Among the 52 studies in Kidney Diseases with a site in Spain, this one is the 47th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 with no phase, and was the 23rd registered.
969 studies on the registry are indexed under Kidney Diseases; 183 are open to participants now.
Browse Kidney Diseases studies →10 of the 52 studies in Kidney Diseases with a site in Spain are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Spain, United States, China and 5 more countries
Eli Lilly and Company · Sites in Spain, Argentina, Australia and 35 more countries
Takeda · Sites in Spain, Belgium, Estonia and 4 more countries
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 6 more countries
Takeda · Sites in Spain, United States, Argentina and 23 more countries
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 128 Kidney Diseases studies recruiting now, 75 (59%) set no upper age limit and 33 (26%) stop at 75 or younger; 25 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 22 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2018.
Median enrollment 150 across the 47 interventional studies, 245 across the 5 observational. Of the 28 that completed or were terminated, 16 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 52 have an industry lead sponsor. The 10 most frequent:
Universidad de León is the lead sponsor of 26 studies on the registry; 1 is open to participants now.
Universidad de León has 1 study filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Diseases with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07483827eleva GmbHA Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy | 2026-11 |
| NCT06809075Hospital Universitari Vall d'Hebron Research InstituteImmunological Reset to Allow Access to HLA Compatible Transplantation in Highly Sensitized Kidney Transplant Candidates Through Non-myeloablative Autologous Stemm Cell Transplantation | 2026-12-01 |
Among the 52 studies in Kidney Diseases with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effectiveness and safety of the therapeutic exercise effects in patients with chronic kidney disease. An randomized clinical trial is carried out. A total sample of 70 patients with chronic kidney disease is recruited and divided into a therapeutic exercise group and a control group. The kidney function (creatinine clearance as main outcome) is measured at baseline and 1 month after treatment start.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Therapeutic Exercise
30 minutes per day of therapeutic exercise
Kidney function
Creatinine clearance
Time frame: Change from Baseline creatinine clearance at 1 month
Started Feb 2018 (actual). Primary completion is estimated for Jun 2021, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de León